This inventor holds 146 USPTO granted patents and 49 published patent applications and 23 EPO patents, primarily in Therapeutic Delivery Systems (CPC class A61B18-1492). Top assignees: The Foundry, Inc., Terumo Kabushiki Kaisha, Medtronic Ardian Luxembourg S.a.r.l.. Active years: 2003-2026.
Inventors with similar research interests:
Company Filing History:
21 out of 57 
17 out of 2,415 
11 out of 236 
Years Active: 2003-2026
Areas of Expertise:
Title: Mark E Deem: A Pioneer in Therapeutic Agent Delivery
Introduction:
Meet Mark E Deem, a renowned innovator and inventor based in Mountain View, CA. With a remarkable track record of 134 patents, Deem has made significant contributions to the field of therapeutic agent delivery. In this article, we will delve into his latest patents, career highlights, and notable collaborations.
Latest Patents:
Deem's latest patents revolve around systems and methods for the delivery of therapeutic agents. Particularly, he focuses on applying fragments of neurotoxins, specifically the active light chain (LC) of the botulinum toxin (BoNT), to produce therapeutic responses in mammalian systems. These innovative methods involve the permeabilization of targeted cell membranes to enable translocation of the BoNT-LC molecule into the cell cytosol. Deem harnesses various delivery systems, including catheter-based, non-invasive, and transdermal approaches, to achieve efficient therapeutic agent delivery.
Career Highlights:
Throughout his illustrious career, Mark E Deem has left an indelible mark on the field of therapeutic agent delivery. Notably, he has contributed to the pioneering work of The Foundry, Inc., a renowned medical device incubator where he played a key role in developing cutting-edge devices and technologies. In collaboration with The Foundry, Inc., Deem's expertise and relentless pursuit of innovation have propelled advancements in therapeutic agent delivery systems.
Collaborations:
Deem has had the privilege of collaborating with esteemed professionals in his field. One notable colleague is Hanson S Gifford, III, an accomplished figure in medical device development. Their collaboration has undoubtedly led to groundbreaking advancements in therapeutic agent delivery systems, setting the stage for future breakthroughs.
Conclusion:
Mark E Deem's extensive patent portfolio is a testament to his significant contributions to the field of therapeutic agent delivery. Through his innovative methods and collaboration with industry leaders, Deem has revolutionized the way therapeutic agents are delivered, paving the way for enhanced treatment options in the medical field. With his relentless pursuit of excellence, we can expect Deem's future endeavors to bring about even more exciting innovations in the realm of medical technology.